Brain tumour imaging with PET:: a comparison between [18F]fluorodopa and [11C]methionine
Brain tumour imaging with PET:: a comparison between [18F]fluorodopa and [11C]methionine
复制标题
DOI：
10.1007/s00259-003-1259-1
复制
发表时间：
2003-11-01
影响因子：
9.1
通讯作者：
Kletter, K
中科院分区：
文献类型：
--
作者：
Becherer, A;Karanikas, G;Kletter, K
脑肿瘤中氨基酸转运的成像比氟-18 2-氟脱氧葡萄糖正电子发射断层扫描（PET）更敏感。该领域最常用的示踪剂是碳-11蛋氨酸（MET），由于其半衰期短，没有回旋加速器的PET中心无法使用。本研究的目的是评估3,4-二羟基-6-[F-18]氟苯丙氨酸（FDOPA）在这种情况下的性能，并与MET进行比较。20例已知幕上脑病变的患者进行了FDOPA和MET的PET扫描。诊断为原发性脑肿瘤18例，转移1例，非肿瘤性脑病变1例。所有20名患者都接受了FDOPA PET扫描（100 MBq， 20分钟），其中19名患者也接受了MET PET扫描（800 MBq， 20分钟）。除1例患者外，其余患者均有组织学诊断。在15例患者中，从既往手术干预中了解组织学；其中5例患者以及4例先前未治疗的患者在PET后获得组织学。在一名未经治疗的患者中，仅通过与MRI的相关性就可以确认PET；10个月后进行了组织学诊断。MET和FDOPA图像在所有患者中都匹配，并且显示所有病变都是热点，比对侧大脑摄取更高。标准化摄取值比，肿瘤/对侧（平均+/-SD）， MET为2.05+/-0.91,FDOPA （NS）为2.04+/-0.53。良性病变，活检显示为局灶性脱髓鞘，假阳性，显示MET和FDOPA摄取增加。我们得出的结论是，FDOPA作为MET的替代品，在成像恶性脑病变中的氨基酸运输中是准确的，目的是可视化重要的肿瘤组织。它结合了F-18良好的物理特性和MET的药理学特性，因此可能是脑肿瘤成像中有价值的PET放射性药物。
Imaging of amino acid transport in brain tumours is more sensitive than fluorine-18 2-fluoro-deoxyglucose positron emission tomography (PET). The most frequently used tracer in this field is carbon-11 methionine (MET), which is unavailable for PET centres without a cyclotron because of its short half-life. The purpose of this study was to evaluate the performance of 3,4-dihydroxy-6-[F-18]fluoro-phenylalanine (FDOPA) in this setting, in comparison with MET. Twenty patients with known supratentorial brain lesions were referred for PET scans with FDOPA and MET. The diagnoses were 18 primary brain tumours, one metastasis and one non-neoplastic cerebral lesion. All 20 patients underwent PET with FDOPA (100 MBq, 20 min p.i.), and 19 of them also had PET scans with MET (800 MBq, 20 min p.i.). In all but one patient a histological diagnosis was available. In 15 subjects, histology was known from previous surgical interventions; in five of these patients, as well as in four previously untreated patients, histology was obtained after PET. In one untreated patient, confirmation of PET was possible solely by correlation with MRI; a histological diagnosis became available 10 months later. MET and FDOPA images matched in all patients and showed all lesions as hot spots with higher uptake than in the contralateral brain. Standardised uptake value ratios, tumour/contralateral side (mean+/-SD), were 2.05+/-0.91 for MET and 2.04+/-0.53 for FDOPA (NS). The benign lesion, which biopsy revealed to be a focal demyelination, was false positive, showing increased uptake of MET and FDOPA. We conclude that FDOPA is accurate as a surrogate for MET in imaging amino acid transport in malignant cerebral lesions for the purpose of visualisation of vital tumour tissue. It combines the good physical properties of F-18 with the pharmacological properties of MET and might therefore be a valuable PET radiopharmaceutical in brain tumour imaging.